Search Results for: covid-19
Articles
Invivyd Announces Continued Neutralizing Activity of PEMGARDA & VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG August 18, 2025
Invivyd, Inc. recently announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA (pemivibart) against the currently dominant and...Traws Pharma Receives Approval to Proceed With Phase 2 COVID Studies With Ratutrelvir August 18, 2025
Traws Pharma, Inc. recently announced receipt from the Human Research Ethics Committee (HREC) of approval to proceed with a Phase 2...Pioneering LNP Expert Dr. Pieter Cullis Joins Hongene’s Scientific Advisory Board August 5, 2025
Hongene, a global CDMO focused on nucleic acid raw materials and medicines, has appointed Dr. Pieter Cullis, a renowned innovator in lipid nanoparticle…
Symbiosis Reaches Major Milestone With Injectable Drug Product July 31, 2025
Symbiosis Pharmaceutical Services recently announced the successful completion of its 1,000th sterile drug product batch, marking a significant milestone in...BioNTech Announces Strategic Transaction to Acquire CureVac June 13, 2025
BioNTech SE and CureVac N.V. recently announced they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to...Vaxart Reports Positive Clinical Data Demonstrating its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses Than its First-Generation Technology June 11, 2025
Vaxart, Inc. recently reported positive topline results from the Phase 1 clinical trial evaluating its second-generation oral pill norovirus vaccine...SPECIAL FEATURE- Outsourcing Formulation Development & Manufacturing: CDMOs Are Making Their Supply Chains More Resilient & Secure June 4, 2025
Contributor Cindy H. Dubin speaks with many CDMO professionals to get their insights and perspectives on the current state of the industry.
PROTEIN BARCODING - Streamlining mRNA Therapeutic & Vaccine Development June 3, 2025
Meredith Carpenter, PhD, reviews how lipid nanoparticles have emerged as a powerful tool for delivery due to their low immunogenicity compared to viral vectors, along with their ability to encapsulate and protect nucleic acids and facilitate their entry into cells.
EXECUTIVE INTERVIEW - Sanner Group: Building a Suite of World-Leading Services for its Customers June 2, 2025
Chris Gilmor, Vice President of Sales, Sanner of America, explains how Sanner’s Advance with Agility™ program helps its partners achieve faster development times and reduce time to market, and how the company embeds sustainable practices into its global business.
IMUNON Announces Oral Presentation Highlighting Unprecedented Survival Data From Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer May 23, 2025
IMUNON recently announced new positive data from its Phase 2 OVATION 2 Study of IMNN-001, an investigational therapy for the...Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles May 12, 2025
Invivyd, Inc. recently announced it has initiated a discovery program for a measles monoclonal antibody (mAb). Multiple healthcare providers (HCPs)...EXECUTIVE INTERVIEW - Botanical Solution Inc.: Launching a Revolution in Economical & Environmentally Sustainable QS-21 Vaccine Adjuvant Production May 7, 2025
Gastón Salinas, CEO of Botanical Solution Inc., discusses his company’s transition from agriculture to pharmaceuticals, addressing the global shortage of QS-21, and developing the QS-21 gold standard vaccine.
CELL-FREE GENE SYNTHESIS - Eliminating Critical Bottlenecks in Genetic Medicine Development April 3, 2025
Marc Unger explores the market trends, challenges, and opportunities new DNA production technologies provide to accelerate genetic advances in healthcare.
CLINICAL TRIALS - Need for Accessibility to Meet FDA Guidance for Decentralized Trials April 3, 2025
Neil Vivian, MSc, says advances in electronic data collection and analysis are helping to make DCTs more accessible to broader and more diverse patient populations. Further innovations, particularly in artificial intelligence technology, are expected to accelerate these trends.
IMUNON Finalizes Phase 3 Study Design With FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer March 24, 2025
IMUNON, Inc. recently announced the US FDA is aligned with the protocol for the Phase 3 pivotal trial, called OVATION...Traws Pharma’s Bird Flu Drug Candidate Presented at ICAR March 21, 2025
Traws Pharma, Inc. recently announced that positive data supporting the potential for tivoxavir marboxil (TXM) as a bird flu treatment...Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine March 18, 2025
Curevo Vaccine recently announced the closing of a $110-million Series B round to advance development of amezosvatein, its vaccine for...IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer February 19, 2025
IMUNON, Inc. recently announced new translational data from ongoing analyses of results from the Company’s Phase 2 OVATION 2 Study of...SPECIAL FEATURE - Analytical Testing – Diverse Demands & Therapies Require Diverse Analyses February 11, 2025
Contributor Cindy H. Dubin highlights how analytical testing has evolved to address diverse pharmaceutical therapeutics in research and development.
LEADERSHIP PANEL - What Will Have the Most Impact on Drug Development in 2025? February 11, 2025
Contributor Cindy H. Dubin asked several life science leaders what they believe will have the greatest impact on drug development in 2025.
